SureNano Science Advances GLP-1 Candidate GEP-44 as Obesity Drug Market Nears $200 Billion

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) is advancing its patented triple agonist peptide GEP-44, targeting GLP-1 and peptide YY receptors, as the global obesity and metabolic disease market continues to expand rapidly. The company, through its subsidiary GlucaPharm Inc., is pursuing a differentiated approach focused on improved efficacy, tolerability and delivery flexibility in a therapeutic category that has become one of the most commercially significant in modern healthcare, with long-term market projections exceeding $200 billion.

SureNano is entering an increasingly competitive GLP-1 landscape dominated by major pharmaceutical companies such as Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Amgen Inc. (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE). Industry momentum continues accelerating as these large-cap incumbents advance next-generation obesity and diabetes therapies through new formulations, expanded indications and reduced-frequency dosing strategies aimed at improving patient access and adherence.

While the current market is dominated by blockbuster GLP-1 products from these incumbents, SureNano is positioning itself as an emerging microcap participant focused on preclinical innovation, alternative delivery technologies and broader platform opportunities that may extend beyond metabolic disease therapeutics. The company’s lead candidate, GEP-44, is a patented peptide designed to target obesity and metabolic disorders with improved tolerability and potential non-injectable delivery, according to a press release dated February 23, 2026.

SureNano Science Ltd. is a Canadian life sciences company focused on acquiring, developing, and advancing innovative pharmaceutical and biotechnology assets with the potential to address large and growing global health markets. The initial business of SureNano Science Ltd. is the sale and distribution of the SureNano(TM) surfactant, a ready-to-mix food grade compound that provides the base for high performance nanoemulsions to create homogeneous and stable products while maximizing bioavailability, clarity, and taste. The company has an exclusive license to distribute the SureNano(TM) surfactant within Canada; Oklahoma, USA; and Colorado, USA.

The company is now developing into a pharmaceutical-focused entity through the advancement of a patented therapeutic candidate designed to address obesity and metabolic disease. For more information, visit the company’s newsroom at https://ibn.fm/SURNF. The full press release is available at https://ibn.fm/g3EkQ.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is SureNano Science Advances GLP-1 Candidate GEP-44 as Obesity Drug Market Nears $200 Billion.

The post SureNano Science Advances GLP-1 Candidate GEP-44 as Obesity Drug Market Nears $200 Billion appeared first on citybuzz.